Merck & Co’s immuno-oncology drug Keytruda ... to overtake AbbVie and Eisai’s anti-inflammatory drug Humira (adalimumab), which is currently the world’s top-selling drug,” says Keshalini ...

Before 2009, Amgen's Vectibix (panitumumab), an inhibitor of epidermal growth factor receptor approved for colon cancer, and Humira (adalimumab ... J&J and in Europe by Merck of Whitehouse ...

SAN FRANCISCO -- More adults with moderate-to-severe Crohn's disease (CD) reached clinical remission after 6 months on ...

Merck & Co/MSD’s three-drug antibiotic Recarbrio ... and Pfizer’s Amsparity – a biosimilar of AbbVie’s immunology blockbuster Humira (adalimumab).

Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey ...

Among TNF inhibitors, the highest persistence was observed with adalimumab. Differences in clinical response ... Glaxo Smith Kline, Janssen, Merck Sharp Dohme, Roche, Servier and Vifor. Patient ...

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...

Now there’s a new one for the list: cancer prevention vaccines. Merck, which makes the commonly used Gardasil shot, has shed 14 per cent of its market value since announcing last week that it ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...